Drugs / Oliceridine
Oliceridine
also known as
TRV130 · Oliceridina · Oliceridine Fumarate · Oliceridine fumarate injection · Olinvyk · Olynvik
Other / unclassified targets OPRM1 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OLINVYK | — | 2020-08-07 | fda.gov ↗ |
Trials 33 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02344303 | Dec 2014 → May 2015 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02169934 | Jun 2014 → Jan 2015 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02083315 | Jul → Aug 2013 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02520297 | Oct 2015 | — | Trevena Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02335294 | Dec 2014 → Jul 2015 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02100748 | Apr → Oct 2014 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02815709 | May → Dec 2016 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02820324 | May → Dec 2016 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02656875 | Dec 2015 → May 2017 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07660380 | Jun → Jul 2026 overdue | — | Shiyou Wei | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07018375 | Jan 2026 → Mar 2027 expected | chronic pain syndrome | Tianjin Medical University General Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06530563 | Aug 2025 → Apr 2026 overdue | — | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07026162 | Jul 2025 → Feb 2026 | — | YanYing Xiao | Completed | No outcome recorded |
| Phase 4 | NCT06619145 | Nov 2024 → Oct 2026 expected | — | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06320041 | Aug 2024 → Dec 2026 expected | — | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06458400 | Jul → Sep 2024 | — | Yuwei Qiu | Completed | No outcome recorded |
| Phase 4 | NCT06411665 | Jul 2024 → Mar 2025 | — | Peking University First Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06454292 | Jun 2024 → Dec 2025 | — | Chun Pan | Unknown | No outcome recorded |
| Phase 4 | NCT05465226 | Apr → Sep 2023 | respiratory underresponsiveness to hypoxia and hypercapnia | University of Tennessee | Completed | No outcome recorded |
| Phase 4 | NCT04979247 | Sep 2021 → Dec 2023 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07707258 | Jul → Sep 2026 expected | — | Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07650812 | Jul 2026 → Dec 2027 expected | bowel dysfunction | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07479446 | Mar 2026 → Aug 2027 expected | cerebellopontine angle tumor | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| — | NCT07307495 | Jan 2026 → Jul 2027 expected | — | Xijing Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07372209 | Oct → Dec 2025 | — | Tangshan Maternal and Child Health Hospital | Completed | No outcome recorded |
| — | NCT07187765 | Sep → Nov 2025 | — | Shiyou Wei | Completed | No outcome recorded |
| — | NCT07154979 | Sep 2025 | — | Shiyou Wei | Completed | No outcome recorded |
| — | NCT07713134 | Aug 2025 → May 2026 | — | Tangshan Maternal and Child Health Hospital | Completed | No outcome recorded |
| — | NCT07112157 | Aug 2025 → Aug 2026 overdue | strabismus | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07097038 | Jul → Dec 2025 overdue | — | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06990893 | Jun 2025 → Oct 2026 expected | — | Anqing Municipal Hospital | Recruiting | No outcome recorded |
| — | NCT06668298 | Nov 2024 → Jun 2025 overdue | — | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06409689 | Jun 2024 → Jun 2025 overdue | — | Tongji Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07306702 Background | Jun 2026 → May 2027 | — | Shenyang Sixth People's Hospital | Withdrawn | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oliceridine | “Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine Surgery” NCT07307495 ↗26“Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery” NCT06320041 ↗ |
| Known as | Oliceridina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2443262 ↗ |
| Known as | Oliceridine Fumarate | “Drug: Oliceridine Fumarate” NCT06454292 ↗ |
| Known as | Oliceridine fumarate injection | “Oliceridine fumarate injection” NCT06530563 ↗ |
| Known as | Olinvyk | “Drug: Oliceridine Injection [Olinvyk]” NCT06530563 ↗ |
| Known as | Olynvik | ChEMBL registry synonym — accepted as the source's own label CHEMBL2443262 ↗ |
| Known as | TRV130 | “A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy” NCT02815709 ↗8“Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid” PMID 31162798 ↗ Jun 2019 |
| Action | Activate | “Biased agonism of the μ-opioid receptor by TRV130 increases analgesia” PMID 24954166 ↗ Jun 20141“Mu opioid receptor agonist” CHEMBL2443262 ↗ |
| Modality | Other / unclassified | “Oliceridine is a G-protein biased μ-opioid receptor agonist” NCT06619145 ↗ |
| Route | Intravenous | “Thirty healthy men received single intravenous injections of the biased ligand TRV130” PMID 24954166 ↗ Jun 2014 |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL2443262 ↗ |